



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/857,876	10/05/2001	John P. McKearn	CU-2557 RJS	2805

7590 12/31/2003

Mr. James M. Warner  
Assistant General Counsel - Pharmacia Corporation  
Global Patent Department  
800 North Lindbergh Blvd.  
St. Louis, MO 63167

EXAMINER

DELACROIX MUIRHEI, CYBILLE

ART UNIT	PAPER NUMBER
----------	--------------

1614

DATE MAILED: 12/31/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

**Application No.**

09/857,876

**Applicant(s)**

MCKEARN ET AL.

**Examiner**

Cybille Delacroix-Muirheid

**Art Unit**

1614

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 10 December 2003.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-22 is/are pending in the application.
- 4a) Of the above claim(s) 5-14 and 16-18 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-4, 15 and 19-22 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. §§ 119 and 120

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All b) ☐ Some \* c) ☐ None of:  
1. ☐ Certified copies of the priority documents have been received.  
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  
\* See the attached detailed Office action for a list of the certified copies not received.
- 13) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.  
a) ☐ The translation of the foreign language provisional application has been received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

### Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_
- 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_

***Detailed Action***

The following is responsive to Applicant's election received Dec. 10, 2003.

Applicant's election of Group I, claims 1-17 and 19-22 with a further election of lung cancer and compound of claim 15 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

Claims 5-14 and 16-18 are withdrawn from consideration.

***Information Disclosure Statement***

Applicant's Information Disclosure Statements received Aug. 13, 2003 and Oct. 19, 2001 have been considered. Please refer to Applicant's copy of the 1449 submitted herewith.

***Specification***

This application does not contain an abstract of the disclosure as required by 37 CFR 1.72(b). An abstract on a separate sheet is required.

***Priority***

If applicant desires priority under 35 U.S.C. 119 based upon a previously filed application, specific reference to the earlier filed application must be made in the instant application.

If the application is a utility or plant application filed under 35 U.S.C. 111(a) on or after November 29, 2000, the specific reference must be submitted during the pendency of the application and within the later of four months from the actual filing date of the

Art Unit: 1614

application or sixteen months from the filing date of the prior application. If the application is a utility or plant application which entered the national stage from an international application filed on or after November 29, 2000, after compliance with 35 U.S.C. 371, the specific reference must be submitted during the pendency of the application and within the later of four months from the date on which the national stage commenced under 35 U.S.C. 371(b) or (f) or sixteen months from the filing date of the prior application. See 37 CFR 1.78(a)(2)(ii) and (a)(5)(ii). This time period is not extendable and a failure to submit the reference required by 35 U.S.C. 119(e) and/or 120, where applicable, within this time period is considered a waiver of any benefit of such prior application(s) under 35 U.S.C. 119(e), 120, 121 and 365(c). A priority claim filed after the required time period may be accepted if it is accompanied by a grantable petition to accept an unintentionally delayed claim for priority under 35 U.S.C. 119(e), 120, 121 and 365(c). The petition must be accompanied by (1) the reference required by 35 U.S.C. 120 or 119(e) and 37 CFR 1.78(a)(2) or (a)(5) to the prior application (unless previously submitted), (2) a surcharge under 37 CFR 1.17(t), and (3) a statement that the entire delay between the date the claim was due under 37 CFR 1.78(a)(2) or (a)(5) and the date the claim was filed was unintentional. The Director may require additional information where there is a question whether the delay was unintentional. The petition should be addressed to: Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

***Claim Rejections—35 USC 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

Art Unit: 1614

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

1. Claims 1, 3-4, 15, 19-22 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the treatment of some cancers, does not reasonably provide enablement for all types of cancers embraced by claims 1, 3 and 4. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

The factors to be considered in determining whether a disclosure meets the enablement requirement of 35 U.S.C. 112, first paragraph, have been described in In re Wands, 8 USPQ2d 1400 (Fed. Cir. 1988). Among these factors are: (1) the nature of the invention; (2) the state of the prior art; (3) the relative skill of those in the art; (4) the predictability or unpredictability of the art; (5) the breadth of the claims; (6) the amount of direction or guidance presented; (7) the presence or absence of working examples; and (8) the quantity of experimentation necessary. When the above factors are weighed, it is the examiner's position that one skilled in the art could not practice the invention without undue experimentation.

**(1) The nature of the invention:**

The claims are drawn to a method for treating neoplasia in a mammal in need thereof by administering an effective amount of a compound such as the one represented by Formula 11.

Art Unit: 1614

**(2) The state of the prior art**

With respect to cancer or neoplasia, this a broad term which encompasses numerous forms of neoplastic diseases, each involving different types of tissues and organs. As recognized in the art, many different antineoplastic drugs are used to treat a variety of cancers, but there is no one drug which is capable of treating all cancers in general.

**(3) The relative skill of those in the art**

The relative skill of those in the art is high.

**(4) The predictability or unpredictability of the art**

The unpredictability of the pharmaceutical and chemical art is high.

**(5) The breadth of the claims**

The claims are very broad and encompass treatment of numerous forms of neoplasias.

**(6) The amount of direction or guidance presented**

Applicant's specification appears to only be enabled for the treatment of neoplasias such as lung cancer, bladder cancer, head and neck cancer and breast cancer. It does not enable one of ordinary skill in the art to use the claimed invention in the treatment of the numerous neoplastic diseases covered by the term "neoplasia." Other than the examples involving only a few cancers, Applicant has not set forth a representative number of examples of cancers, which would be treated by the claimed compounds.

**(7) The presence or absence of working examples**

The only working examples in the specification involve the description of various regimens in treating the specific cancers described above.

**(8) The quantity of experimentation necessary**

Since (1) the art recognizes that no one compound is capable of treating the numerous neoplastic diseases encompassed by the term "cancer"; (2) since the claims require the treatment of numerous types of neoplasias, and (3) since Applicant's specification does not provide a representative number of cancers which can be treated with the compounds of the invention, one of ordinary skill in the art would be burdened with undue experimentation to determine which of the many cancers embraced by Applicant's claims would be treated by the claimed compounds.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

2. Claims 3, 15, 19-22 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
3. Claim 3 recites the limitation "said mammal" in line 2. There is insufficient antecedent basis for this limitation in the claim. In claim 3, line 1, "subject" should be cancelled and replaced with --mammal--.
4. Claims 21-22 recite the limitation "the combination" in line 1. There is insufficient antecedent basis for this limitation in the claim.
5. Claims 19-20 recite the limitation "the combination" in line 1. There is insufficient antecedent basis for this limitation in the claim.

***Claim Rejections—35 USC 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application-indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

6. Claims 1-4, 15 and 19-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bender et al., 5,753,653 in view of Bumol et al., 5,348,887.



Art Unit: 1614

Bender et al. disclose a method for inhibiting the activity of metalloproteinases by administering an effective amount of a compound represented by Formula I, wherein a specific compound to be administered is disclosed at line 24 of Table I (elected compound). Furthermore, Bender et al. teach that the compounds may be useful in treating tumor growth, invasion or metastasis, wherein a specific tumor to be inhibited may be lung tumors. Please see abstract; Table I, claims 15-16; col. 45, lines 44-67.

Bender does not teach combining the administration of the metalloproteinase inhibitor with radiation therapy; however, the Examiner refers to Bumol et al, which disclose that the most effective forms of therapy for the treatment of lung cancer is radiation therapy and surgery. Please see col. 1, lines 27-32.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the method of Bender to include radiation therapy because one of ordinary skill in the art would reasonably expect the additive effect of the two forms of therapy to effectively treat lung cancer. Such a modification would have been motivated by the reasonable expectation of effectively and comprehensively treating a patient suffering from lung cancer.

With respect to claims 19-22, it would have been obvious to one of ordinary skill in the art to either sequentially or simultaneously administer the two forms of therapy with the reasonable expectation that either one would effectively treat a patient suffering from lung cancer.

### ***Conclusion***

Claims 1-4, 15, 19-22 are rejected.

Art Unit: 1614

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cybille Delacroix-Muirheid whose telephone number is 703-306-3227. The examiner can normally be reached on Mon-Fri from 9:30 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel, can be reached on (703) 308-4725. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

CDM

Dec. 29, 2003

  
Cybille Delacroix-Muirheid  
Patent Examiner Group 1600